Hexima is pleased to announce that it has completed the bookbuild for a placement to raise $10.0 million. In addition, Hexima proposes to launch a share purchase plan for Eligible Shareholders in Australia and New Zealand (SPP) to raise up to a further $1.0 million.
The new ordinary shares to be issued in the Placement and SPP will rank equally with existing Hexima Shares.
Michael Aldridge, Managing Director & CEO of Hexima said, “We have been very pleased with the support of our existing Shareholders and with the quality of healthcare-focused institutional investors that we have added to our register.
“We remain on track to deliver results from our ongoing phase IIb clinical trial in Q2 2022. This capital will accelerate our development plans for pezadeftide into US and international markets, allowing us to immediately initiate preparations for our phase III trials, which we expect to commence in Q4 2022, and potentially adds another development program to our pipeline” Michael added.
